Predictive Value of Red Cell Volume Distribution Width-to-Platelet Ratio in Staging Liver Fibrosis in Chronic HCV-Infected Patients

Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy

A Study of Hepatocellular Carcinoma in Chronic Hepatitis C Patients Received Direct Acting Antiviral Drugs

Occurrence of hepatocellular carcinoma following direct antiviral agents (DAA) therapy

Hepatocellular Carcinoma after Treatment of Cirrhotic Hepatitis C Virus Patients with Direct Acting Antiviral Treatment

Clinicoepidemiologic Study of Hepatocellular Carcinoma among HCV Induced Compensated Cirrhotic Patients who Achieved Sustained Virologic Response with Direct Acting Antiviral Dru

Innovative Diagnostic Model Based on Beta-Catenin, Tumor Necrosis Factor-Alpha, Interleukin 21 and CA19.9 Biomarkers for Follow-up of HCC Development After DAA Therapy for HCV In

Assessment of Incidence of Hepatocellular Carcinoma among Hepatitis C Patients Who Achieved Sustained Virological Response with Direct Acting Antiviral Agents (DAAs)

Changes in CD4 and CD8 after Interventional Management of Hepatocellular Carcinoma

Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis